Treats CMV retinitis. ANDA 204750, held by Aurobindo Pharma Ltd. Valganciclovir Hydrochloride.
As of Nov 16, 2026, ANDA 204750 (Valganciclovir Hydrochloride), held by Aurobindo Pharma Ltd, was first approved by FDA on Mar 31, 2016, with 5 approved supplements and 0 published complete response letters.
Valganciclovir tablets are a deoxynucleoside analogue cytomegalovirus (CMV) DNA polymerase inhibitor indicated for: Adult Patients Treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS). Prevention of CMV disease in kidney, heart, and kidney-pancreas transplant patients at high risk. Pediatric Patients Prevention of CMV disease in kidney and heart transplant patients at high risk. 1.1 Adult Patients Treatment of Cytomegalovirus (CMV) Retinitis: Valganciclovir tablets are indicated for the treatment of CMV retinitis in patients with acquired immunodeficiency syndrome (AIDS).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 31, 2016 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Valganciclovir HydrochlorideEQ 450MG BASE · tablet;oral | Valganciclovir Hydrochloride | Rx |
| Jun 27, 2022 | Supplement 8Labeling · Standard review | Approved | None posted |
| Jun 27, 2022 | Supplement 10Labeling · Standard review | Approved | None posted |
| Mar 12, 2020 | Supplement 2Labeling · Standard review | Approved | None posted |
| Mar 12, 2020 | Supplement 3Labeling · Standard review | Approved | None posted |
| Mar 12, 2020 | Supplement 5Labeling · Standard review | Approved | None posted |
| Mar 31, 2016 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters